Bolt Biotherapeutics Inc. logo

Bolt Biotherapeutics Inc.

BOLT | NASDAQ
Chart Builder DCF Calculator
$3.59
+$0.03 (+0.84%)
At close: Sep 21, 2026, 4:00 PM ET
$3.59
$0 (0.00%)
After-hours: Sep 21, 2026, 4:10 PM ET

Market Data

Market Cap
$6.84M
Enterprise Value
$10.92M
Beta
1.09
Average Volume
24.45K
Shares Outstanding (Diluted)
1.69M
Shares Change YoY
-11.84%
Institutional Ownership
32.80%
Exchange
NASDAQ
ISIN
US0977022039

Price Performance

Price Change 1M
-1.6%
Price Change 3M
-15.7%
Price Change 6M
-20.2%
Price Change YTD
-38.0%
Price Change 1Y
-32.8%
Price Change 3Y
-82.7%
Price Change 5Y
-98.6%
1M CAGR (ann.)
-8.0%
1Y CAGR (ann.)
-33.7%
5Y CAGR (ann.)
-59.7%
All-Time CAGR
-60.3%

Valuation

PE Ratio
-0.22
Forward PE
N/A
PEG Ratio
0.00
Forward PEG
-0.02
PS Ratio
1.47
Forward PS
2.00
PB Ratio
0.55
P/FCF Ratio
-0.22
P/Adj. FCF Ratio
-0.20
P/OCF Ratio
-0.19
EV/Sales
2.32
EV/EBIT
-0.38
EV/EBITDA
-0.39
EV/FCF
-0.35
Earnings Yield
-445.7%
FCF Yield
-457.1%
Adj. FCF Yield
-494.0%

Financial Health

Net Cash
$17.6M
Total Debt
$21.62M
Cash & Short-Term Investments
$17.6M
Total Assets
$40.34M
Current Ratio
2.61
Quick Ratio
2.61
Debt / Equity Ratio
1.71
Debt / EBITDA
-0.78
Debt / FCF
-0.69
OCF / Debt
-1.45
Interest Coverage
0.00
Altman Z-Score
-18.22
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
95.7%
Operating Profit Margin
-623.0%
EBITDA Margin
-591.9%
Net Profit Margin
-611.5%
FCF Margin
-671.0%
Adj. FCF Margin
-725.1%
SBC / Revenue
54.1%
SBC Impact (per share)
-8.1%

Returns

Return on Assets
-71.2%
Return on Equity
-126.2%
Return on Invested Capital
-82.3%
Return on Capital Employed
-90.2%
Return on Tangible Assets
-71.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
-11.5%
Revenue CAGR 5Y
-0.2%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-91.8%
EPS CAGR 5Y
-54.6%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
33.2%
FCF CAGR 5Y
20.7%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Hold
Analyst Count
8
EPS Growth Next 3Y
-40.7%
Revenue Growth Next 3Y
19.4%
Earnings Date
Nov 10, 2026
EPS Estimate (next Q)
-$3.89
EPS Growth Est (next Q)
4.6%
Revenue Est (next Q)
$68.33K
Revenue Growth Est (next Q)
-96.8%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$4
Price Target Upside
11.4%

Cash Flow

Operating Cash Flow
$-31.45M
Free Cash Flow
$-31.54M
Adj. Free Cash Flow
$-34.08M
FCF Per Share
-$18.65
OCF Per Share
-$18.60
OCF/S Ratio
-669.2%

Income Statement

Revenue
$4.7M
Gross Profit
$4.5M
Operating Income
$-29.28M
EBITDA
$-27.82M
Net Income
$-28.74M
EPS (Diluted)
-$16
Revenue / Employee
$204.35K
Profit / Employee
$-1.25M
Employees
23

© 2026 bestshares.com. All rights reserved.